Our team in Finland has grown significantly this year, and for that, we owe a huge thank you to our excellent clients and the outstanding work delivered by our consultants.
Our Finnish Modelling, Access & Strategy team combines extensive experience from […]
Alexandra Wennberg is on her way to Barcelona for the EASL 2026 Congress ✈️
Over the coming days, she will meet clients and colleagues to discuss real-world evidence in liver disease and share perspectives from the Quantify Research Liver Disease Platform.
Nordic […]
Oskar Ström and Johan Liseth Hansen will be attending the ASCO 2026 Annual Meeting in Chicago from 29 May to 2 June.
They will be meeting partners and discussing the Quantify Research Nordic Oncology RWD Platform — a study-ready data asset […]
After several days of insightful discussions, reconnecting with colleagues, and exchanging perspectives on the future of HEOR and RWE, we are now heading home from ISPOR 2026.
It has been a highly productive […]
A strong theme ran through Day 2:
Stakeholders have stopped debating whether real world evidence belongs at the decision table. The conversation has moved to how to generate RWE that is credible, transparent, and ready to inform real decisions.
Across sessions on […]
From a packed calendar of back-to-back meetings and new connections to wrapping up the night with a Dixieland band and great food with the athagoras Group […]
Starting Day 1 of ISPOR with the full team from the athagoras Group… We are looking forward to connecting with clients, new and old, colleagues and building new relationships.
Watch this space!
[…]
A strong research career often starts with curiosity and consistency.
We are happy to share that Sanjana has transitioned from intern to Research Analyst within Quantify Research’s Evidence Review and Synthesis team in India.
Since joining as an intern in October 2025, she […]
Quantify Research will be attending ISPOR 2026 in Philadelphia (17–20 May) as part of the athagoras Group.
Joining from Quantify:
• Puneet Kaushik
• Kelsi Smith
• Abraham Choong
TLV’s recent decision on Fabhalta provides further evidence of how Sweden applies higher acceptable ICERs in very rare conditions.
Fabhalta was assessed for a very rare, severe chronic kidney disease population. Following three-party negotiations, TLV’s base case, including the confidential agreement, […]